四環醫藥(00460.HK)攜研究成果出席ASCO
四環醫藥(00460.HK)宣布,日前攜研究成果出席於美國芝加哥舉行的第59屆美國臨床腫瘤學會(ASCO),會上展示了旗下軒竹生物自主研發的創新型CDK4/6抑制劑(口比)羅西尼單藥治的療多線治療後進展的HR+/HER2-轉移性乳腺癌的良好療效,在研究結果獲得全球業界高度認可的同時,也進一步驗證了軒竹生物的企業價值。
四環醫藥旗下創新藥子公司軒竹生物自主研發的針對HR+/HER2-晚期乳腺癌的、具有全新結構的CDK4/6抑制劑,也是內地首個進行單藥末線註冊性臨床試驗的CDK4/6抑制劑。
四環醫藥控股集團主席兼執行董事車馮升表示,集團旗下在研品類的研發和商業化進程正在有序推進,而今次攜研究結果亮相國際舞台,意味著集團的創新能力已普遍獲得國際生物製藥同行認可,同時證明公司成長確定性正在不斷提高;未來,集團將以強勁研發實力和體系化競爭優勢為驅動因數,積極成為一間投資價值和成長空間皆優的企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.